Ra Pharma's mid-stage study underway for myasthenia gravis candidate RA101495 SC [Seeking Alpha]
RA PHARMACEUTICALS (RARX)
Last ra pharmaceuticals earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rapharma.com/news-investors
Company Research
Source: Seeking Alpha
Ra Pharma's mid-stage study underway for myasthenia gravis candidate RA101495 SCDosing is underway in a Phase 2 clinical trial evaluating Ra Pharmaceuticals' (NASDAQ:RARX) RA101495 SC in patients with generalized myasthenia gravis, an autoimmune disorder characterized by skeletal muscle weakness.Thestudy will enroll ~36 subjects who will be randomized to receive one of two doses of RA101495 or placebo once-daily for 12 weeks. According to ClinicalTrials.gov, the estimated completion date is April 2019.RA101495 SC is subcutaneously administered complement 5 inhibitor. It is also being developed for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and lupus nephritis.Click to subscribe to real-time analytics on RARXNow read:Aclaris - FDA Approved Its First Drug, And What Now? »
Show less
Read more
Impact Snapshot
Event Time:
RARX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RARX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RARX alerts
High impacting RA PHARMACEUTICALS news events
Weekly update
A roundup of the hottest topics